Press release
May 1, 2020

Sosei Heptares notes that Enerzair® Breezhaler® (QVM149) has been recommended for approval in the European Union for treating uncontrolled asthma


  • Positive opinion received from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)
  • Enerzair® Breezhaler® (QVM149) is a once-daily, potential first-in-class inhaled LABA/LAMA/ICS combination for asthma patients in the EU

 

Tokyo, Japan and London, UK, 1 May 2020 – Sosei Group Corporation (“the Company”; TSE: 4565) notes that its strategic alliance partner Novartis (SWX: NOVN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval in the European Union of Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of uncontrolled asthma in adult patients. Uncontrolled patients are those whose asthma is not adequately controlled with a maintenance combination of a long acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.

The European Commission (EC) reviews the CHMP recommendation and usually delivers its final decision in approximately two months. If the EC follows this recommendation and approves Enerzair® Breezhaler®, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients. Additional regulatory filings for QVM149 are currently underway in multiple countries, including Switzerland, Japan and Canada.

The full announcement from Novartis, including data from the clinical trial programs supporting the CHMP recommendation, is available at www.novartis.com.

Glycopyrronium bromide and certain intellectual property relating to its use and formulation were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura Group PLC (LSE: VEC). Novartis is responsible for the development and commercialization of Enerzair® Breezhaler® (QVM149). Under the agreement, Sosei Heptares is entitled to certain development and sales-based milestones, and royalties on net sales upon successful commercialisation of Enerzair® Breezhaler®.

While the CHMP positive opinion does not trigger a milestone payment, Sosei Heptares will be eligible to receive a $5m milestone on final approval by the EC and thereafter a low-single digit royalty on net sales.  The event reported therefore has no immediate impact on the consolidated financial results for the accounting period ending December 2020.

Shinichi Tamura, President and CEO of Sosei Heptares, commented: “The recommendation for the approval of Enerzair® Breezhaler® is a great step towards it becoming available to the many uncontrolled asthma patients in the European Union. The extensive clinical trial program conducted by Novartis demonstrated robust efficacy and safety data with once-daily IND/GLY/MF showing significant improvements in lung function over a standard-of-care therapy If approved, this novel product would become the first LABA/LAMA/ICS combination therapy for uncontrolled asthma administered using a single inhaler with additional features in-built to support treatment adherence. We look forward to the final decision by the EC in the next two months and further updates in relation to filings in other countries over the coming year.”

 

About Uncontrolled Asthma

Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health and financial burden when not adequately controlled1,2. Despite current therapy, over 40% of patients with asthma at Global Initiative for Asthma (GINA) Step 3, and over 45% at GINA Steps 4 and 5 remain uncontrolled3,4. Patients with uncontrolled asthma may downplay or underestimate the severity of their disease and are at a higher risk of exacerbation, hospitalization or death5,6,7. Barriers, such as treatment mismatch, safety issues with an oral corticosteroid and ineligibility for biologics, have created an unmet medical need in asthma8,9.

 

References

  1. GBD Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma. 2017. Available at: https://doi.org/10.1016/S2213-2600(17)30293-X
  2. AAFA. My Life With Asthma Survey Findings Report. Available at: https://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf. Accessed April 2020.
  3. Chung KF et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343-73.
  4. Fang J et al. Demographic, clinical characteristics and control status of pediatric, adolescent, and adult asthma patients by GINA Step in a US longitudinal cohort. Am J Resp Crit Care Med 2018;197:A1903
  5. Peters SP et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100(7):1139-1151.
  6. Katsaounou P et al. Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res 2018;4(4):00076-2018.
  7. Price D et al. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009.
  8. Price D, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018;11:193-204.
  9. Albers FC et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma 2018;55(2):152-160.

 

Enerzair® and Breezhaler® are registered trademarks of Novartis AG.

 

– ENDS –

 


 DOWNLOAD PDF